Who Owns Aveeno?

Aveeno's sustainability profile is reported under Kenvue's annual ESG disclosures. Kenvue's Healthy Lives Mission includes commitments across three pillars: healthy people, healthy planet, and healthy communities. The healthy planet pillar includes targets to reduce carbon emissions, increase recycled and recyclable packaging, and improve water stewardship in manufacturing.

Aveeno does not hold B Corp certification or an independently verified product-level sustainability certification as of June 2026. Kenvue publishes aggregate environmental data in its annual ESG report, but does not disclose brand-level carbon footprints or brand-specific packaging recyclability rates for Aveeno separately.

Kenvue has committed to ensuring that 100% of its plastic packaging is recyclable, reusable, or compostable by 2025. As of Kenvue's most recent published ESG data (2024), the company disclosed progress toward this target but did not confirm full achievement. Aveeno's product packaging includes plastic bottles and tubes across its body care, baby, and facial care lines. Kenvue's packaging sustainability claims are cross-referenced against its published ESG report rather than against independent auditor verification.

Aveeno sources oats for its colloidal oatmeal ingredient from agricultural suppliers. Kenvue has not published a public supplier sustainability audit specifically for oat sourcing. Aveeno does not carry organic certification for its oat ingredients.

Colloidal oatmeal, Aveeno's core ingredient, received FDA recognition as a skin protectant active ingredient under the FDA's OTC Monograph system. This is a regulatory designation, not a marketing award, and it means formulations meeting monograph standards are categorized as drug products with clinically defined claims for relieving minor skin irritation, itching, and dryness. This designation distinguishes Aveeno from competitors using oat extracts without meeting the colloidal oatmeal monograph specification.

In March 2026, Kenvue announced a three-year research collaboration between Aveeno and Mayo Clinic focused on preclinical and clinical research into Aveeno's Triple Oat technology for compromised skin conditions. The collaboration was announced through Kenvue's media relations in March 2026 and is verifiable through the Kenvue press release archived at Kenvue's investor relations site.

Aveeno has consistently appeared in the top tier of dermatologist-recommended skincare brand rankings published by dermatology professional organizations. Independent dermatologist surveys in the United States have listed Aveeno among the top recommended brands for eczema and sensitive skin care for multiple consecutive years.

Aveeno has faced several significant product recalls and controversies, primarily related to sunscreen safety issues and product contamination concerns. While the brand maintains a strong reputation for gentle skincare, these incidents have impacted consumer trust and led to increased regulatory scrutiny of the brand's product safety protocols.

July 2021 Sunscreen Benzene Recall: In July 2021, Johnson & Johnson (then-owner of Aveeno) issued a voluntary recall of several Aveeno aerosol sunscreen products after confirming the presence of benzene, a known carcinogen, in testing conducted by independent laboratory Valisure. The recall affected specific lots of Aveeno Protect + Refresh aerosol sunscreen products. Benzene is not an intended ingredient in sunscreen products, and its presence was attributed to manufacturing contamination issues. This recall was part of a broader industry issue affecting multiple sunscreen brands.

Sunscreen Cancer Lawsuits: The benzene contamination incident led to numerous consumer lawsuits against Johnson & Johnson and Aveeno, alleging that the contaminated sunscreen products exposed users to cancer risks. These lawsuits sought compensation for consumers who developed cancer or other health issues allegedly related to benzene exposure from the recalled sunscreen products. The legal proceedings highlighted concerns about quality control in sunscreen manufacturing and testing protocols.

Aveeno Baby Lotion Bacteria Recall: Approximately 2,200 tubes of Aveeno Baby Lotion were recalled after the FDA detected high levels of bacteria in one lot of the product. The recall was initiated as a precautionary measure to prevent potential infections in infants, who are particularly vulnerable to bacterial contamination. This incident raised concerns about manufacturing quality control and sterile processing procedures for baby care products.

Valisure Independent Testing Findings: Independent testing laboratory Valisure found benzene in multiple Johnson & Johnson sunscreen products, including Aveeno brands, at levels exceeding FDA and Environmental Protection Agency limits. Valisure's testing revealed that some products contained benzene levels "well over the acceptable limits," leading to broader concerns about contamination in aerosol sunscreen products across the industry.